# BCL2A1

## Overview
BCL2A1 is a gene that encodes the BCL2 related protein A1, a member of the Bcl-2 family known for its anti-apoptotic properties. This protein plays a pivotal role in regulating apoptosis, primarily by inhibiting cell death, and is predominantly expressed in hematopoietic cells. BCL2A1 is characterized by its structural motifs, including the BH1-4 domains, which are essential for its function in apoptosis inhibition. The protein is localized to the mitochondria, where it contributes to maintaining mitochondrial integrity and cellular homeostasis. BCL2A1 interacts with various pro-apoptotic proteins, such as Bax and Bak, to prevent apoptosis, and is a direct transcriptional target of the NF-kappa B signaling pathway. Its expression and function are significant in immune cell survival and have been implicated in cancer progression and resistance to chemotherapy, making it a potential therapeutic target (Schenk2017Characterisation; Li2021Inhibitors; Zong1999The).

## Structure
The BCL2A1 protein, also known as Bfl-1, is a member of the Bcl-2 family and is characterized by its anti-apoptotic function. It is encoded by a 14-kb DNA segment on human chromosome 15 (15q24.3) and consists of three exons that translate into a protein with 175 amino acids (Li2021Inhibitors). The protein contains the BH1-4 motifs typical of anti-apoptotic proteins, which are crucial for its function in apoptosis inhibition (Li2021Inhibitors). 

Structurally, BCL2A1 features eight alpha-helices, with a long and narrow hydrophobic groove formed by the a2, a3, a5, a7, and a8 helices. This groove is essential for its interaction with pro-apoptotic proteins and contains the BH1-3 domains, characterized by a negative charge in its central region (Li2021Inhibitors). The protein shares structural similarities with Mcl-1 but has unique features, such as the C55 residue, which can form a specific disulfide bond with C175, affecting its conformation and binding capacity (Li2021Inhibitors).

BCL2A1 is targeted to the mitochondria due to its amphipathic C-terminus, which aids in membrane localization (Li2021Inhibitors). The protein's structure and interactions are critical for its role in regulating apoptosis and its potential as a therapeutic target in cancer therapy.

## Function
The BCL2A1 gene encodes a pro-survival protein that is part of the Bcl-2 family, which plays a crucial role in regulating apoptosis by inhibiting cell death. This protein is predominantly expressed in hematopoietic cells and is involved in maintaining cell survival by preventing apoptosis, particularly in immune cells (Schenk2017Characterisation; Zong1999The). BCL2A1 is a direct transcriptional target of the NF-kappa B (NF-κB) signaling pathway, which is activated in response to various stimuli, including inflammatory signals and TNF-alpha (Zong1999The). 

In the context of immune function, BCL2A1 is crucial for the survival of certain cell types, such as conventional dendritic cells (cDCs) and neutrophils, by modulating their response to apoptotic signals (Schenk2017Characterisation; Chuang1998A1). The protein is active in the mitochondria, where it contributes to mitochondrial integrity and cellular homeostasis, thereby influencing immune response and inflammation (Chuang1998A1). BCL2A1's role in blocking apoptosis is significant in promoting cell survival during immune responses and in conditions of cellular stress (Zong1999The).

## Clinical Significance
Alterations in the expression and function of the BCL2A1 gene are implicated in various cancers, contributing to tumor survival and resistance to chemotherapy. In breast cancer, BCL2A1 is upregulated, which is associated with worse patient survival and resistance to chemotherapeutic agents, including BH3 mimetics like ABT-737 (Kønig2019Alterations). In B-cell lymphomas, particularly those with CARD11 gain-of-function mutations, BCL2A1 is overexpressed independently of B-cell receptor signaling, leading to resistance against Bcl2 inhibition therapies. This resistance can be counteracted by MALT1 inhibitors, which reduce BCL2A1 expression and enhance apoptosis when combined with BCL2 inhibitors (Decombis2023CARD11).

In anaplastic large cell lymphoma (ALCL), BCL2A1 is regulated by NPM-ALK activity and is crucial for the survival of ALK-positive cells. Silencing BCL2A1 induces apoptosis, highlighting its role as a potential therapeutic target (Piva2006Functional). BCL2A1 is also implicated in resistance to therapies in mantle cell lymphoma, where its expression is elevated at relapse and contributes to resistance by buffering pro-apoptotic BH3-only proteins (Decombis2023CARD11). These findings underscore the clinical significance of BCL2A1 in cancer progression and treatment resistance.

## Interactions
BCL2A1, also known as Bfl-1, is an anti-apoptotic protein that interacts with several pro-apoptotic proteins to inhibit apoptosis. It binds to Bax and Bak, preventing their dimerization and subsequent mitochondrial membrane depolarization, which blocks the release of apoptotic factors and inhibits the caspase pathway (Li2021Inhibitors). BCL2A1 also interacts with BH3-only proteins such as Bim and PUMA, neutralizing their pro-apoptotic effects (Li2021Inhibitors; Kim2019Prenylated). It has a high affinity for Bak and Bid, while it weakly binds to BIK, NOXA, and HRK, similar to Mcl-1 (Li2021Inhibitors).

BCL2A1 can bind to the splicing variant of mouse ING1 homologous (mINGh) to obstruct mINGh-induced epithelial cell death (Li2021Inhibitors). It also interacts with prenylated Rab acceptor 1 (RABAC1), which inhibits its anti-apoptotic activity and induces apoptosis in AGS gastric cancer cells (Kim2019Prenylated). The Nur77 peptide binds to BCL2A1, interacting with three distinct segments of the protein chain, which correspond to a crevice on the Bfl-1 fold that shares a wall with the BH3-binding pocket (Godoi2016Orphan). These interactions highlight BCL2A1's role in regulating apoptosis and its potential as a therapeutic target in cancer treatment.


## References


[1. (Li2021Inhibitors) Xue Li, Junwei Dou, Qidong You, and Zhengyu Jiang. Inhibitors of bcl2a1/bfl-1 protein: potential stock in cancer therapy. European Journal of Medicinal Chemistry, 220:113539, August 2021. URL: http://dx.doi.org/10.1016/j.ejmech.2021.113539, doi:10.1016/j.ejmech.2021.113539. This article has 26 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.ejmech.2021.113539)

[2. (Schenk2017Characterisation) Robyn L Schenk, Selma Tuzlak, Emma M Carrington, Yifan Zhan, Susanne Heinzel, Charis E Teh, Daniel H Gray, Lin Tai, Andrew M Lew, Andreas Villunger, Andreas Strasser, and Marco J Herold. Characterisation of mice lacking all functional isoforms of the pro-survival bcl-2 family member a1 reveals minor defects in the haematopoietic compartment. Cell Death &amp; Differentiation, 24(3):534–545, January 2017. URL: http://dx.doi.org/10.1038/cdd.2016.156, doi:10.1038/cdd.2016.156. This article has 60 citations.](https://doi.org/10.1038/cdd.2016.156)

[3. (Chuang1998A1) Peter I. Chuang, Esther Yee, Aly Karsan, Robert K. Winn, and John M. Harlan. A1 is a constitutive and inducible bcl-2 homologue in mature human neutrophils. Biochemical and Biophysical Research Communications, 249(2):361–365, August 1998. URL: http://dx.doi.org/10.1006/bbrc.1998.9155, doi:10.1006/bbrc.1998.9155. This article has 78 citations and is from a peer-reviewed journal.](https://doi.org/10.1006/bbrc.1998.9155)

[4. (Piva2006Functional) Roberto Piva, Elisa Pellegrino, Michela Mattioli, Luca Agnelli, Luigia Lombardi, Francesco Boccalatte, Giulia Costa, Bruce A. Ruggeri, Mangeng Cheng, Roberto Chiarle, Giorgio Palestro, Antonino Neri, and Giorgio Inghirami. Functional validation of the anaplastic lymphoma kinase signature identifies cebpb and bcl2a1 as critical target genes. Journal of Clinical Investigation, 116(12):3171–3182, December 2006. URL: http://dx.doi.org/10.1172/jci29401, doi:10.1172/jci29401. This article has 128 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci29401)

[5. (Godoi2016Orphan) Paulo H.C. Godoi, Rachel P. Wilkie-Grantham, Asami Hishiki, Renata Sano, Yasuko Matsuzawa, Hiroko Yanagi, Claudia E. Munte, Ya Chen, Yong Yao, Francesca M. Marassi, Hans R. Kalbitzer, Shu-ichi Matsuzawa, and John C. Reed. Orphan nuclear receptor nr4a1 binds a novel protein interaction site on anti-apoptotic b cell lymphoma gene 2 family proteins. Journal of Biological Chemistry, 291(27):14072–14084, July 2016. URL: http://dx.doi.org/10.1074/jbc.M116.715235, doi:10.1074/jbc.m116.715235. This article has 24 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.M116.715235)

[6. (Decombis2023CARD11) Salomé Decombis, Celine Bellanger, Yannick Le Bris, Candice Madiot, Jane Jardine, Juliana Carvalho Santos, Delphine Boulet, Christelle Dousset, Audrey Menard, Charlotte Kervoelen, Elise Douillard, Philippe Moreau, Stephane Minvielle, Agnes Moreau-Aubry, Benoit Tessoulin, Gael Roue, Nicolas Bidère, Steven Le Gouill, Catherine Pellat-Deceunynck, and David Chiron. Card11 gain of function upregulates bcl2a1 expression and promotes resistance to targeted therapies combination in b-cell lymphoma. Blood, 142(18):1543–1555, November 2023. URL: http://dx.doi.org/10.1182/blood.2023020211, doi:10.1182/blood.2023020211. This article has 7 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/blood.2023020211)

[7. (Kim2019Prenylated) Jong-Tae Kim, Hee Jun Cho, Mi-Young Cho, Jeewon Lim, Eun Sun Park, Jong-Seok Lim, and Hee Gu Lee. Prenylated rab acceptor rabac1 inhibits anti-apoptotic protein bcl2a1 and induces apoptosis. Biochemical and Biophysical Research Communications, 513(4):940–946, June 2019. URL: http://dx.doi.org/10.1016/j.bbrc.2019.04.080, doi:10.1016/j.bbrc.2019.04.080. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2019.04.080)

[8. (Zong1999The) W.-X. Zong, L. C. Edelstein, C. Chen, J. Bash, and C. Gelinas. The prosurvival bcl-2 homolog bfl-1/a1 is a direct transcriptional target of nf-kappa b that blocks tnfalpha -induced apoptosis. Genes &amp; Development, 13(4):382–387, February 1999. URL: http://dx.doi.org/10.1101/gad.13.4.382, doi:10.1101/gad.13.4.382. This article has 574 citations.](https://doi.org/10.1101/gad.13.4.382)

[9. (Kønig2019Alterations) Simon Mathis Kønig, Vendela Rissler, Thilde Terkelsen, Matteo Lambrughi, and Elena Papaleo. Alterations of the interactome of bcl-2 proteins in breast cancer at the transcriptional, mutational and structural level. PLOS Computational Biology, 15(12):e1007485, December 2019. URL: http://dx.doi.org/10.1371/journal.pcbi.1007485, doi:10.1371/journal.pcbi.1007485. This article has 40 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1371/journal.pcbi.1007485)